文献速递新发突发、热带与寄生虫病

乌干达氨基喹啉、抗叶酸和青蒿素耐药潜在介导因子的流行率变化

Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda.
PubMed 文献 · J Infect Dis · 2021-01-01

该研究在2018和2019年从乌干达16个站点采集样本,通过多种分子检测方法分析疟原虫耐药相关基因多态性。结果显示,与氨基喹啉类耐药相关的PfCRT 76T流行率下降但站点间差异显著,与磺胺多辛-乙胺嘧啶高水平耐药相关的dhfr 164L和dhps 581G突变在多个站点流行率高,而青蒿素延迟清除相关的kelch 469Y和675V突变在乌干达北部多个站点流行率上升。结论提示关键抗疟药物疗效可能受限的突变正在传播。

要点

  • 乌干达北部青蒿素延迟清除相关kelch 469Y和675V突变流行率上升,分别高达23%和41%。
  • 磺胺多辛-乙胺嘧啶高水平耐药相关dhfr 164L和dhps 581G突变在多个站点流行率高,分别高达80%和67%。
  • 氨基喹啉耐药相关PfCRT 76T流行率下降但站点间差异大,2018年0-46%,2019年0-23%。

核心结论

  • 研究显示可能限制关键抗疟药物疗效的突变在乌干达传播,包括青蒿素延迟清除相关kelch 469Y和675V突变以及磺胺多辛-乙胺嘧啶高水平耐药相关dhfr 164L和dhps 581G突变。

研究设计与样本

  • 2018和2019年从乌干达16个站点采集样本,采用连接酶检测反应荧光微球、分子倒置探针、双脱氧测序和定量聚合酶链反应等方法分析耐药相关基因多态性。

主要发现

  • 与氨基喹啉耐药相关的PfCRT 76T流行率下降,2018年0-46%,2019年0-23%,站点间差异显著。
  • 其他与哌喹耐药相关的PfCRT多态性和plasmepsin-2/3扩增未发现。
  • 2019年PfMDR1 86Y突变在所有站点均缺失,1246Y突变在16个站点中的14个流行率≤20%,未发现基因扩增。
  • 与磺胺多辛-乙胺嘧啶高水平耐药相关的dhfr 164L流行率高达80%,dhps 581G流行率高达67%,在多个站点均高。
  • 与青蒿素延迟清除相关的kelch 469Y和675V突变在乌干达北部多个站点流行率上升,分别高达23%和41%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Uganda, artemether-lumefantrine is recommended for malaria treatment and sulfadoxine-pyrimethamine for chemoprevention during pregnancy, but drug resistance may limit efficacies. METHODS: Genetic polymorphisms associated with sensitivities to key drugs were characterized in samples collected from 16 sites across Uganda in 2018 and 2019 by ligase detection reaction fluorescent microsphere, molecular inversion probe, dideoxy sequencing, and quantitative polymerase chain reaction assays. RESULTS: Considering transporter polymorphisms associated with resistance to aminoquinolines, the prevalence of Plasmodium falciparum chloroquine resistance transporter (PfCRT) 76T decreased, but varied markedly between sites (0-46% in 2018; 0-23% in 2019); additional PfCRT polymorphisms and plasmepsin-2/3 amplifications associated elsewhere with resistance to piperaquine were not seen. For P. falciparum multidrug resistance protein 1, in 2019 the 86Y mutation was absent at all sites, the 1246Y mutation had prevalence ≤20% at 14 of 16 sites, and gene amplification was not seen. Considering mutations associated with high-level sulfadoxine-pyrimethamine resistance, prevalences of P. falciparum dihydrofolate reductase 164L (up to 80%) and dihydropteroate synthase 581G (up to 67%) were high at multiple sites. Considering P. falciparum kelch protein propeller domain mutations associated with artemisinin delayed clearance, prevalence of the 469Y and 675V mutations has increased at multiple sites in northern Uganda (up to 23% and 41%, respectively). CONCLUSIONS: We demonstrate concerning spread of mutations that may limit efficacies of key antimalarial drugs.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Asua V, Conrad MD, Aydemir O, et al. Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda. J Infect Dis. 2021. PMID: 33146722. doi:10.1093/infdis/jiaa687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。